DR. REDDY'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,909 INR | -0.21% |
|
-6.12% | +1.91% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 280B 3.35B 4.59B | Sales 2025 * | 300B 3.6B 4.92B | Capitalization | 986B 11.8B 16.13B |
|---|---|---|---|---|---|
| Net income 2024 | 55.78B 668M 913M | Net income 2025 * | 55.44B 664M 908M | EV / Sales 2024 | 3.43 x |
| Net cash position 2024 | 64.59B 773M 1.06B | Net cash position 2025 * | 90.85B 1.09B 1.49B | EV / Sales 2025 * | 2.98 x |
| P/E ratio 2024 |
18.4
x | P/E ratio 2025 * |
17.7
x | Employees | 25,863 |
| Yield 2024 |
0.65% | Yield 2025 * |
0.76% | Free-Float | 91.55% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dr. Reddy's Laboratories Limited
More recommendations
More press releases
More news
| 1 day | -0.21% | ||
| 1 week | -6.12% | ||
| Current month | -4.77% | ||
| 1 month | -2.88% | ||
| 3 months | -6.74% | ||
| 6 months | +9.02% | ||
| Current year | +1.91% |
1 week
5 818.10
6 114.95
1 month
5 818.106 419.90
Current year
5 520.656 505.90
1 year
4 384.056 505.90
3 years
3 654.006 505.90
5 years
2 351.206 505.90
10 years
1 872.956 505.90
| Managers | Title | Age | Since |
|---|---|---|---|
Erez Israeli
CEO | Chief Executive Officer | 57 | 18-04-01 |
Parag Agarwal
DFI | Director of Finance/CFO | - | 20-11-01 |
| Chairman | 56 | 93-01-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gunupati Prasad
CHM | Chairman | 63 | 86-04-07 |
| Chairman | 56 | 93-01-17 | |
Kalpana Morparia
BRD | Director/Board Member | 74 | 07-06-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 5,909 | -0.21% | 170,564 |
| 24-05-10 | 5,921 | +0.74% | 296,180 |
| 24-05-09 | 5,877 | -2.96% | 506,907 |
| 24-05-08 | 6,056 | -3.22% | 988,140 |
| 24-05-07 | 6,258 | -0.57% | 317,354 |
Delayed Quote NSE India S.E., May 13, 2024 at 07:43 am
More quotes
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows:
- sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines;
- sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services;
- other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc.
Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Sector
Pharmaceuticals
Calendar
2024-07-23
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
5,919
INR
Average target price
6,100
INR
Spread / Average Target
+3.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.98% | 684B | |
| +30.34% | 568B | |
| -3.52% | 361B | |
| +18.59% | 329B | |
| +4.07% | 284B | |
| +16.21% | 240B | |
| +9.66% | 208B | |
| -6.83% | 200B | |
| +7.09% | 166B |
- Stock Market
- Equities
- DRREDDY Stock
- DRREDDY Stock